Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.

Monguillon V, Marston NA, Bohula EA, Park JG, Kuder JF, Murphy SA, De Ferrari GM, Leiter LA, Nicolau JC, Ebenbichler C, Sinnaeve P, Goudev A, Budaj A, Averkov O, Tokgözoğlu L, Blankstein R, Vinereanu D, Giugliano RP, Sabatine MS, O'Donoghue ML

Open source

DOI: 10.1161/circulationaha.126.080999
Published: 2026 Jun 23
Container: Circulation
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1161/circulationaha.126.080999,
  title = {Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.},
  author = {Monguillon V and Marston NA and Bohula EA and Park JG and Kuder JF and Murphy SA and De Ferrari GM and Leiter LA and Nicolau JC and Ebenbichler C and Sinnaeve P and Goudev A and Budaj A and Averkov O and Tokgözoğlu L and Blankstein R and Vinereanu D and Giugliano RP and Sabatine MS and O'Donoghue ML},
  year = {2026},
  journal = {Circulation},
  doi = {10.1161/circulationaha.126.080999},
  url = {https://doi.org/10.1161/circulationaha.126.080999}
}

RIS

TY  - JOUR
TI  - Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.
AU  - Monguillon V
AU  - Marston NA
AU  - Bohula EA
AU  - Park JG
AU  - Kuder JF
AU  - Murphy SA
AU  - De Ferrari GM
AU  - Leiter LA
AU  - Nicolau JC
AU  - Ebenbichler C
AU  - Sinnaeve P
AU  - Goudev A
AU  - Budaj A
AU  - Averkov O
AU  - Tokgözoğlu L
AU  - Blankstein R
AU  - Vinereanu D
AU  - Giugliano RP
AU  - Sabatine MS
AU  - O'Donoghue ML
PY  - 2026
JO  - Circulation
DO  - 10.1161/circulationaha.126.080999
UR  - https://doi.org/10.1161/circulationaha.126.080999
ER  -

APA

V, M., NA, M., EA, B., JG, P., JF, K., SA, M., GM, D. F., LA, L., JC, N., C, E., P, S., A, G., A, B., O, A., L, T., R, B., D, V., RP, G., MS, S., & ML, O. (2026). Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.. Circulation. https://doi.org/10.1161/circulationaha.126.080999

Source records

pubmed · retrieved 2026-09-26T14:46:33.388Z